US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
US4657760A
(en)
|
1979-03-20 |
1987-04-14 |
Ortho Pharmaceutical Corporation |
Methods and compositions using monoclonal antibody to human T cells
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
CA1338518C
(en)
|
1987-09-23 |
1996-08-13 |
Joyce M. Zarling |
Antibody heteroconjugates for the killing of hiv-infected cells
|
DE68925971T2
(de)
|
1988-09-23 |
1996-09-05 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
DE69029036T2
(de)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
Bispezifische reagenzien für die aids-therapie
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
EP0586505A1
(en)
|
1991-05-14 |
1994-03-16 |
Repligen Corporation |
Heteroconjugate antibodies for treatment of hiv infection
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US7018809B1
(en)
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
ES2202310T3
(es)
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
ES2304786T3
(es)
|
1995-04-27 |
2008-10-16 |
Amgen Fremont Inc. |
Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
AU7378096A
(en)
|
1995-09-28 |
1997-04-17 |
Alexion Pharmaceuticals, Inc. |
Porcine cell interaction proteins
|
DE19544393A1
(de)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistische herbizide Mischungen
|
DK1500329T3
(da)
|
1996-12-03 |
2012-07-09 |
Amgen Fremont Inc |
Humane antistoffer, der specifikt binder TNF-alfa
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
ATE531812T1
(de)
|
1997-12-05 |
2011-11-15 |
Scripps Research Inst |
Humanisierung von nager-antikörpern
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
AU782626B2
(en)
|
1999-10-04 |
2005-08-18 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
ES2528794T3
(es)
|
2000-04-11 |
2015-02-12 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス,インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
US20040119010A1
(en)
|
2002-11-01 |
2004-06-24 |
The Regents Of The University Of Colorado |
Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
|
US8066997B2
(en)
|
2002-12-20 |
2011-11-29 |
Anders Nykjaer |
Modulation of activity of neurotrophins
|
EP1682170A2
(en)
|
2003-11-07 |
2006-07-26 |
Lay Line Genomics SpA |
Compositions able to prevent neurodegenerative processes and methods of assaying the same
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
JP2008526205A
(ja)
|
2004-12-31 |
2008-07-24 |
ジェネンテック・インコーポレーテッド |
Br3に結合するポリペプチド及びその使用
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
US8877714B2
(en)
|
2005-06-14 |
2014-11-04 |
Raptor Pharmaceutical Inc. |
Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
|
CN105330741B
(zh)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
US9062126B2
(en)
|
2005-09-16 |
2015-06-23 |
Raptor Pharmaceuticals Inc. |
Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
|
FR2896881B1
(fr)
|
2006-01-31 |
2008-04-18 |
Biomerieux Sa |
Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
|
EP4316465A3
(en)
|
2006-03-15 |
2024-04-24 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
CA2651567A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
MX2009002893A
(es)
|
2006-09-18 |
2009-07-10 |
Raptor Pharmaceutical Inc |
Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
|
WO2008052016A2
(en)
|
2006-10-23 |
2008-05-02 |
Columbia University |
The sortilin-related receptor sorl1 is functionally and genetically associated with alzheimer's disease
|
WO2008076262A2
(en)
|
2006-12-15 |
2008-06-26 |
Merck & Co., Inc. |
Receptor for amyloid beta and uses thereof
|
UY30776A1
(es)
|
2006-12-21 |
2008-07-03 |
Medarex Inc |
Anticuerpos cd44
|
HUE048781T2
(hu)
|
2006-12-21 |
2020-08-28 |
H Lundbeck As |
Proneurotrofinok aktivitásának modulációja
|
WO2008086452A2
(en)
|
2007-01-10 |
2008-07-17 |
Columbia University |
Treatment and prevention of alzheimer's disease
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
CL2008002153A1
(es)
*
|
2007-07-24 |
2009-06-05 |
Amgen Inc |
Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
|
EP2193146B1
(en)
|
2007-09-14 |
2016-05-25 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
PT2235064E
(pt)
|
2008-01-07 |
2016-03-01 |
Amgen Inc |
Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
|
EP2274327B1
(en)
|
2008-04-27 |
2019-03-27 |
H. Lundbeck A/S |
Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
|
ES2680222T3
(es)
|
2008-05-22 |
2018-09-05 |
H. Lundbeck A/S |
Modulación de los receptores con dominio Vps10p para el tratamiento de la enfermedad cardiovascular
|
US20160359907A1
(en)
|
2015-06-02 |
2016-12-08 |
Vmware, Inc. |
Automatically auditing virtual machines for security hardening compliance
|
EP2307042B1
(en)
|
2008-06-25 |
2014-03-26 |
H. Lundbeck A/S |
Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
|
PE20141433A1
(es)
|
2008-07-16 |
2014-10-19 |
Inst Research In Biomedicine |
Anticuerpos neutralizantes de citomegalovirus humano
|
WO2010022175A1
(en)
|
2008-08-19 |
2010-02-25 |
Yale University |
Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
|
WO2010028333A2
(en)
|
2008-09-08 |
2010-03-11 |
Mayo Foundation For Medical Education And Research |
Methods and devices for ligating tubular structures
|
CN102439041B
(zh)
|
2008-12-19 |
2016-05-04 |
H.隆德贝克有限公司 |
用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
|
FR2945538B1
(fr)
|
2009-05-12 |
2014-12-26 |
Sanofi Aventis |
Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
|
WO2011041584A2
(en)
|
2009-09-30 |
2011-04-07 |
President And Fellows Of Harvard College |
Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
|
US20130115222A1
(en)
|
2010-06-15 |
2013-05-09 |
Cornell University |
Methods of limiting microvascular damage following acute myocardial ischemia
|
EP4219805A1
(en)
|
2010-07-16 |
2023-08-02 |
Adimab, LLC |
Antibody libraries
|
US20130336988A1
(en)
|
2010-11-17 |
2013-12-19 |
New York University |
Methods for treating early stage or mild neurological disorders
|
AU2012269720B2
(en)
|
2011-06-13 |
2015-01-22 |
Csl Limited |
Antibodies against G-CSFR and uses thereof
|
CN103748114B
(zh)
|
2011-08-23 |
2017-07-21 |
罗切格利卡特公司 |
T细胞活化性双特异性抗原结合分子
|
US9822366B2
(en)
|
2012-11-02 |
2017-11-21 |
The Brigham And Women's Hospital, Inc. |
Sortilin 1 is a novel inducer of vascular calcification
|
EP2991679A4
(en)
|
2013-04-29 |
2016-12-07 |
Adimab Llc |
POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE
|
JP6462680B2
(ja)
|
2013-07-09 |
2019-01-30 |
アネクソン,インコーポレーテッド |
抗補体因子C1q抗体及びその使用
|
CA2938577A1
(en)
|
2014-02-04 |
2015-08-13 |
New York University |
Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
|
EP3105594A1
(en)
|
2014-02-12 |
2016-12-21 |
H. Lundbeck A/S |
Use of sortilin as biomarker for affective/mood disorders
|
EP3122765A1
(en)
|
2014-03-26 |
2017-02-01 |
Goran Landberg |
Agents inhibiting granulin for treatment of cancer
|
EP3193942B1
(en)
|
2014-08-11 |
2020-03-25 |
Shire Human Genetic Therapies, Inc. |
Lysosomal targeting and uses thereof
|
EP3280441B1
(en)
|
2015-04-07 |
2021-09-29 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
US10849992B1
(en)
*
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
US20160331746A1
(en)
|
2015-05-12 |
2016-11-17 |
University Of South Florida |
Sortilin-Binding Small Molecules for Increasing Glucose Uptake
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
US11390656B2
(en)
|
2015-08-04 |
2022-07-19 |
New York University |
Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
|
US10085969B1
(en)
|
2016-02-12 |
2018-10-02 |
University Of South Florida |
Sortilin binding compounds, formulations, and uses thereof
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
US11833187B2
(en)
|
2017-10-23 |
2023-12-05 |
The Brigham And Women's Hospital, Inc. |
Materials and methods for extracellular vessicle-associated diseases
|
MX2020012518A
(es)
|
2018-06-18 |
2021-02-16 |
Denali Therapeutics Inc |
Proteinas de fusion que comprenden progranulina.
|
EP3844190A4
(en)
|
2018-08-24 |
2022-06-08 |
Transfert Plus, S.E.C. |
METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGEN MIMETICISM
|
WO2020051624A1
(en)
|
2018-09-11 |
2020-03-19 |
Grophin Pty Ltd |
Methods and compositions for improving recovery from a brain injury
|
EP3666281A1
(en)
|
2018-12-14 |
2020-06-17 |
Insusense ApS |
Compositions comprising sortilin-1
|
EP3942049A4
(en)
|
2019-03-20 |
2023-10-18 |
President And Fellows Of Harvard College |
PROGRANULIN AUGMENTATION THERAPY BASED ON ANTI-SENSE OLIGONUCLEOTIDES IN NEURODEGENERATIVE DISEASES
|
US20200392229A1
(en)
|
2019-06-11 |
2020-12-17 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|